Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests
Executive Summary
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
You may also be interested in...
MedTech Europe IVDR Impact Report: The Good, The Bad And The Ugly
The outcome of a survey by trade association MedTech Europe shows that while more than 90% of companies benefited from the extension of IVDR transition deadlines, significant issues remain that could see many diagnostics disappear from the market.
When Is An IVD A CDx? EU IVDR Guidance Updated To Include Flowchart
The EU Medical Device Coordination Group has issued a second revision to its guidance document on classification rules for in vitro diagnostics under the new regulation. The addition of a flowchart to determine when an IVD is a companion diagnostic is one key change.
EU IVDR Milestone: Cancer Biomarker Test First To Get A Companion Diagnostic CE Marking
A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.